The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Open accessAbstract
BACKGROUND: Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS: In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of at least 1.5 times the upper limit of the normal range to receive subcutaneous pasireotide at a dose of 600 μg (82 patients) or 900 μg (80 patients) twice daily. Patients with urinary free cortisol not exceeding 2 times the upper limit of the normal range and not exceeding the baseline level at month 3 continued to receive their randomly assigned dose; all others received an additional 300 μg twice daily. The primary end point was a urinary free cortisol level at or below the upper limit of the normal range at month 6 without an increased dose. Open-label treatment continued through month 12. RESULTS: Twelve of the 82 patients in the 600-μg group and 21 of the 80 patients in the 900-μg group met the primary end point. The median urinary free cortisol level decreased by approximately 50% by month 2 and remained stable in both groups. A normal urinary free cortisol level was achieved more frequently in patients with baseline levels not exceeding 5 times the upper limit of the normal range than in patients with higher baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, and clinical signs and symptoms of Cushing's disease diminished. Pasireotide was associated with hyperglycemia-related adverse events in 118 of 162 patients; other adverse events were similar to those associated with other somatostatin analogues. Despite declines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatment initiation and then stabilized; treatment with a glucose-lowering medication was initiated in 74 of 162 patients. CONCLUSIONS: The significant decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its potential use as a targeted treatment for corticotropin-secreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00434148.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mean UFC is routinely used in clinical practice and research to monitor disease control and treatment response in patients with CS treated with medical therapy (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The restoration of cortisol circadian rhythm following medical therapy has not been investigated or established for most medications used to treat CS, and it is not routinely measured to determine treatment response (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In clinical trials, the efficacy of steroidogenesis inhibitors and pituitary-directed therapies in patients with CS was primarily evaluated by the normalization of cortisol secretion per UFC (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Self-citationNewell-Price, J. D. C., BERTAGNA, X. Y., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,258
Self-citationTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationIncidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt‐Rasmussen, U., Hagen, C., Jørgensen, J. O. L., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 763
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Morbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.117 · Cited by 505
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 474
Pivonello, R., Martino, M. C. D., Cappabianca, P., Leo, M. D., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328
Self-citation
Research works printed but not linked: 1
- Cavagnini F, 2001, Ann Endocrinol (Paris), 62, 168
Cited by
Sorted by citations
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Self-citationDiagnosis and Treatment of Pituitary Adenomas: A Review
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 933
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationLacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., Martino, M. C. D., Newell-Price, J. D. C., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 694
Self-citationPituitary-Tumor Endocrinopathies.
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 466
Raverot, G., Burman, P., McCormack, A. I., Heaney, A. P., Petersenn, S., POPOVIC, V. M., Trouillas, J., Dekkers, O. M., & _, _. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 593
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., Leo, M. D., Cozzolino, A., & Colao, A. A. L. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 478
Self-citationMultisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 421
Diagnosis and Management of Pituitary Adenomas: A Review
Tritos, N. A., & Miller, K. K. (2023) · JAMA · doi:10.1001/jama.2023.5444 · Cited by 331
Ketoconazole in Cushing's disease: is it worth a try?
Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285
Somatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas‐Salas, J., & Álvarez‐Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 268
Caroli, A., Perico, N., Perna, A., Antiga, L., Brambilla, P., Pisani, A., Visciano, B., Imbriaco, M., Messa, P., Cerutti, R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61407-5 · Cited by 260
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 273
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H., Lupp, A., Korbonits, M., Castano, J. P., Wester, H., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 264
Feelders, R. A., Pulgar, S. J., Kempel, A., & Pereira, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1095 · Cited by 265
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
Henry, R. R., Ciaraldi, T. P., Armstrong, D. A., Burke, P., Ligueros‐Saylan, M., & Mudaliar, S. R. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1771 · Cited by 256
Cortinovis, M., Perico, N., Ruggenenti, P., Remuzzi, A., & Remuzzi, G. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00559-y · Cited by 214
Cushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210
Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review
Ritzel, K., Beuschlein, F., Mickisch, A., Oßwald, A., Schneider, H. J., Schopohl, J., & Reincke, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1470 · Cited by 201
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
The hypertension of Cushing's syndrome
Isidori, A. M., Graziadio, C., Paragliola, R. M., Cozzolino, A., Ambrogio, A. G., Colao, A., Corsello, S. M., & Pivonello, R. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000415 · Cited by 220
Self-citationMetabolic comorbidities in Cushing's syndrome
Ferraù, F., & Korbonits, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0354 · Cited by 226
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 182
Gadelha, M. R., Gatto, F., Wildemberg, L. E., & Fleseriu, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01961-x · Cited by 183
Cushing’s disease: the burden of illness
Pivonello, R., Martino, M. D. D., de Leo, M., Simeoli, C., & Colao, A. (2017) · Endocrine · doi:10.1007/s12020-016-0984-8 · Cited by 153
Self-citationPreda, V. A., Sen, J., Karavitaki, N., & Grossman, A. B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0274 · Cited by 170
Management of hormone-secreting pituitary adenomas
Mehta, G. U., & Lonser, R. R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now130 · Cited by 174
Therapeutic uses of somatostatin and its analogues: Current view and potential applications
Rai, U., Thrimawithana, T. R., Valéry, C., & Young, S. A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.007 · Cited by 168
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
Lacroix, A., Gu, F., Gallardo, W., Pivonello, R., Yu, Y., Witek, P., Boscaro, M., Salvatori, R., Yamada, M., Tauchmanovà, L., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30326-1 · Cited by 161
Self-citationAdvances in the medical treatment of Cushing's syndrome
Feelders, R. A., Newell-Price, J. D. C., Pivonello, R., Nieman, L. K., Hofland, L. J., & Lacroix, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30155-4 · Cited by 160
Self-citationSomatostatin receptor ligands and resistance to treatment in pituitary adenomas
Ramos, D. C., & Fleseriu, M. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0011 · Cited by 157
Colao, A., Block, C. E. M. D., Gaztambide, M. S., Kumar, S., Seufert, J., & Casanueva, F. F. (2013) · Pituitary · doi:10.1007/s11102-013-0483-3 · Cited by 152
Self-citationHigh variability in baseline urinary free cortisol values in patients with Cushing's disease
Petersenn, S., Newell-Price, J. D. C., Findling, J. W., Gu, F., Maldonado, M., Sen, K., Salgado, L. R., Colao, A. A. L., Biller, B. M. K., & Pasireotide B2305 Study Group (2013) · Clinical Endocrinology · doi:10.1111/cen.12259 · Cited by 149
Self-citationRaff, H., Sharma, S. T., & Nieman, L. K. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130035 · Cited by 141
Medical Treatment of Cushing's Disease
Feelders, R. A., & Hofland, L. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3126 · Cited by 146
Salomon, M. P., Wang, X., Marzese, D. M., Hsu, S. C., Nelson, N. E., Zhang, X., Matsuba, C., Takasumi, Y., Ballesteros‐Merino, C., Fox, B. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2206 · Cited by 146
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Cushing’s syndrome: from physiological principles to diagnosis and clinical care
Raff, H., & Carroll, T. (2015) · The Journal of Physiology · doi:10.1113/jphysiol.2014.282871 · Cited by 137
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
Pivonello, R., Ferrigno, R., Martino, M. C. D., Simeoli, C., Paola, N. D., Pivonello, C., Barba, L., Negri, M., de Angelis, C., & Colao, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00648 · Cited by 130
Self-citationPeptide Receptor Targeting in Cancer: The Somatostatin Paradigm
Barbieri, F., Bajetto, A., Pattarozzi, A., Gatti, M., Würth, R., Thellung, S., Corsaro, A., Villa, V., Nizzari, M., & Florio, T. (2013) · International Journal of Peptides · doi:10.1155/2013/926295 · Cited by 121
Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications
Barbot, M., Zilio, M., & Scaroni, C. M. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101380 · Cited by 126
Pivonello, R., Petersenn, S., Newell-Price, J. D. C., Findling, J. W., Gu, F., Maldonado, M., Trovato, A., Hughes, G., Salgado, L. R., Lacroix, A., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12431 · Cited by 117
Self-citationCabergoline for Cushing’s disease: a large retrospective multicenter study
Ferrière, A., Cortet, C., Chanson, P., Delemer, B., Caron, P. J., Chabre, O., Reznik, Y., Bertherat, J. Y., Rohmer, V., Briet, C., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0662 · Cited by 114
Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study
Breitschaft, A., Hu, K., Reséndiz, K. H., Darstein, C., & Golor, G. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.011 · Cited by 113
Chinezu, L., Vasiljevic, A., Jouanneau, E., François, P., Borda, A., Trouillas, J., & Raverot, G. (2014) · Human Pathology · doi:10.1016/j.humpath.2013.08.007 · Cited by 106
Potential Role for Retinoic Acid in Patients with Cushing's Disease
Giraldi, F. P., Ambrogio, A. G., Andrioli, M., Sanguin, F., Karamouzis, I., Corsello, S. M., Scaroni, C. M., Arvat, E., Pontercorvi, A., & Cavagnini, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2328 · Cited by 114
Barbot, M., Albiger, N. M. E., Ceccato, F., Zilio, M., Frigo, A. C., Denaro, L., Mantero, F., & Scaroni, C. M. (2013) · Pituitary · doi:10.1007/s11102-013-0475-3 · Cited by 112
Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study
Mehta, G. U., Ding, D., Patibandla, M. R., Kano, H., Sisterson, N. D., Su, Y.-H., Kršek, M., Nabeel, A. M., El-Shehaby, A. M. N., Abdelkarim, K., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01385 · Cited by 103
Öberg, K., & Lamberts, S. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-16-0151 · Cited by 90
Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis
Broersen, L. H. A., Jha, M., Biermasz, N. R., Pereira, A. M., & Dekkers, O. M. (2018) · Pituitary · doi:10.1007/s11102-018-0897-z · Cited by 101
The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas
Lu, M., Ya, W., & Zhan, X. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00330 · Cited by 103
ANNIVERSARY REVIEW: Octreotide, 40 years later
Lamberts, S. W. J., & Hofland, L. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0074 · Cited by 100
Management of aggressive pituitary adenomas and pituitary carcinomas
Heaney, A. P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1413-6 · Cited by 97
Cives, M., Kunz, P. L., Morse, B., Coppola, D., Schell, M. J., Campos, T., Nguyen, P. T., Nandoskar, P., Khandelwal, V, & Strosberg, J. R. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-14-0360 · Cited by 96
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
Barbot, M., Ceccato, F., & Scaroni, C. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00321 · Cited by 94
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Colao, A., Auriemma, R., & Pivonello, R. (2015) · Pituitary · doi:10.1007/s11102-015-0677-y · Cited by 87
Self-citationBERTAGNA, X. Y., & Guignat, L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3200 · Cited by 93
A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome
Reincke, M., Ritzel, K., Oßwald, A., Berr, C., Stalla, G. K., Hallfeldt, K. K. J., Reisch, N., Schopohl, J., & Beuschlein, F. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0265 · Cited by 91
Medical management of Cushing’s disease: what is the future?
Fleseriu, M., & Petersenn, S. (2012) · Pituitary · doi:10.1007/s11102-012-0397-5 · Cited by 88
Self-citationIlluminating somatostatin analog action at neuroendocrine tumor receptors
Reubi, J. C., & Schönbrunn, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.10.001 · Cited by 88
THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome
Daniel, E., & Newell-Price, J. D. C. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1014 · Cited by 88
Self-citationRecent Updates on the Diagnosis and Management of Cushing's Syndrome
Nieman, L. K. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.2.139 · Cited by 85
Functioning Pituitary Adenomas – Current Treatment Options and Emerging Medical Therapies
Varlamov, E. V., McCartney, S., & Fleseriu, M. (2019) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2019.15.1.30 · Cited by 87
Somatostatin analogs: does pharmacology impact antitumor efficacy?
Chalabi, M., Duluc, C., Caron, P., Vezzosi, D., Guillermet-Guibert, J., Pyronnet, S., & Bousquet, C. (2014) · Trends in endocrinology and metabolism · doi:10.1016/j.tem.2013.11.003 · Cited by 66
Perico, N., Ruggenenti, P. L., Perna, A., Caroli, A., Trillini, M., Sironi, S., Pisani, A., Riccio, E., Imbriaco, M., Dugo, M., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002777 · Cited by 81
DIAGNOSIS OF ENDOCRINE DISEASE: Diagnostic approach to TSH-producing pituitary adenoma.
Tjörnstrand, A., & Nyström, H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1029 · Cited by 70
Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
Silverstein, J. M. (2016) · Pituitary · doi:10.1007/s11102-016-0734-1 · Cited by 79
Diabetes Mellitus Secondary to Cushing’s Disease
Barbot, M., Ceccato, F., & Scaroni, C. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00284 · Cited by 80
SCHMID, H. A., Brue, T. C., Colao, A., Gadelha, M. R., Shimon, I., Kapur, K., Pedroncelli, A. M., & Fleseriu, M. (2016) · Endocrine · doi:10.1007/s12020-016-0895-8 · Cited by 76
Self-citationSomatostatin system: molecular mechanisms regulating anterior pituitary hormones
Eigler, T., & Ben-Shlomo, A. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0034 · Cited by 75
Cushing's syndrome: Treatment and new therapeutic approaches
Ferrière, A., & Tabarin, A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101381 · Cited by 76
Approach to the Patient Treated with Steroidogenesis Inhibitors
Castinetti, F., Nieman, L. K., Reincke, M., & Newell-Price, J. D. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab122 · Cited by 79
Self-citationCyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease
Liu, N., Araki, T., Ramos, D. C., Jiang, H., Ben-Shlomo, A., Tone, Y., Tone, M., & Melmed, S. K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1606 · Cited by 72
Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
Shamsi, B. H., Chatoo, M., Xu, X. K., Xu, X., & Chen, X. Q. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.652363 · Cited by 71
An individualized approach to the management of Cushing disease
Fleseriu, M., Varlamov, E., Hinojosa-Amaya, J. M., Langlois, F., & Melmed, S. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00868-7 · Cited by 59
SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary
Lee, M., Lupp, A., Mendoza, N., Martin, N. M., Beschorner, R., Honegger, J. B., Schlegel, J., Shively, T., Pulz, E., Schulz, S., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0472 · Cited by 70
Metyrapone treatment in Cushing’s syndrome: a real-life study
Ceccato, F., Zilio, M., Barbot, M., Albiger, N. M. E., Antonelli, G., Plebani, M., Watutantrige‐Fernando, S., Sabbadin, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine · doi:10.1007/s12020-018-1675-4 · Cited by 69
Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?
Guérin, C., Taïeb, D., Treglia, G., Brue, T. C., Lacroix, A., Sebag, F. A., & Castinetti, F. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0541 · Cited by 69
Fleseriu, M., Hamrahian, A. H., Hoffman, A. R., Kelly, D. F., & Katznelson, L. (2016) · Endocrine Practice · doi:10.4158/ep161512.dscr · Cited by 68
Pasireotide—a novel somatostatin receptor ligand after 20 years of use
Bolanowski, M., Kałużny, M., Witek, P., & Jawiarczyk-Przybyłowska, A. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09710-3 · Cited by 68
Caccese, M., Barbot, M., Ceccato, F., Padovan, M., Gardiman, M. P., Fassan, M., Denaro, L., Emanuelli, E., D’Avella, D., Scaroni, C. M., et al. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000856 · Cited by 68
Managing Cushing’s disease: the state of the art
Colao, A., Boscaro, M., Ferone, D., & Casanueva, F. F. (2014) · Endocrine · doi:10.1007/s12020-013-0129-2 · Cited by 66
Self-citationNishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
Efficacy of medical treatment in C ushing's disease: a systematic review
Gadelha, M. R., & Neto, L. V. (2013) · Clinical Endocrinology · doi:10.1111/cen.12345 · Cited by 65
Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
He, X., Findling, J. W., & Auchus, R. J. (2022) · Pituitary · doi:10.1007/s11102-022-01218-y · Cited by 68
Self-citationFleseriu, M., Molitch, M., Gross, C., Schteingart, D., Vaughan, T. B., & Biller, B. (2013) · Endocrine Practice · doi:10.4158/ep12149.ra · Cited by 55
Self-citationHistone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease
Lu, J., Chatain, G. P., Bugarini, A., Wang, X., Maric, D., Walbridge, S., Zhuang, Z., & Chittiboina, P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00464 · Cited by 64
Pituitary Adenomas: From Diagnosis to Therapeutics
Banskota, S., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050494 · Cited by 71
Schopohl, J., Gu, F., Rubens, R., Gaal, L. V., Bertherat, J. Y., Ligueros‐Saylan, M., Trovato, A., Hughes, G., Salgado, L. R., Boscaro, M., et al. (2014) · Pituitary · doi:10.1007/s11102-014-0618-1 · Cited by 62
Self-citationRaverot, G., Burman, P., Abreu, A. P., Heaney, A. P., van Hulsteijn, L. T., Lin, A. L., Marcus, H. J., McCormack, A. I., Minniti, G., Petersenn, S., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf100 · Cited by 74
Self-citationCeccato, F., Lombardi, G., Manara, R., Emanuelli, E., Denaro, L., Milanese, L., Gardiman, M. P., Bertorelle, R., Scanarini, M., D’Avella, D., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1702-0 · Cited by 61
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
Samson, S. L., Gu, F., Feldt‐Rasmussen, U., Zhang, S., Yu, Y., Witek, P., Kalra, P., Pedroncelli, A. M., Pultar, P., Jabbour, N., et al. (2021) · Pituitary · doi:10.1007/s11102-021-01161-4 · Cited by 61
Self-citationPetersenn, S., Salgado, L. R., Schopohl, J., Portocarrero-Ortiz, L. A., Arnaldi, G., Lacroix, A., Scaroni, C. M., Ravichandran, S., Kandra, A., & Biller, B. M. K. (2017) · Endocrine · doi:10.1007/s12020-017-1316-3 · Cited by 58
Self-citationManagement of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide
Reznik, Y., Bertherat, J. Y., Borson‐Chazot, F., Brue, T. C., Chanson, P., Cortet‐Rudelli, C., Delemer, B., Tabarin, A., Bisot-Locard, S., & Vergès, B. L. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.10.005 · Cited by 59
Treating canine Cushing’s syndrome: Current options and future prospects
Sanders, K., Kooistra, H. S., & Galac, S. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2018.09.014 · Cited by 56
Treatment of Cushing's disease: a mechanistic update
Ramos, D. C., & Fleseriu, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0300 · Cited by 55
Mifepristone for Management of C ushing's Syndrome
Morgan, F. H., & Laufgraben, M. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1202 · Cited by 56
Metadata
- Authors
- Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., & Biller, B. M. K.
- Affiliations
- Federico II University Hospital (IT)
- University of Duisburg-Essen (DE)
- University of Sheffield (GB)
- Medical College of Wisconsin (US)
- Peking Union Medical College Hospital (CN)
- Novartis (Switzerland) (CH)
- Universidade de São Paulo (BR)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 914-924
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133418708
- Semantic Scholar
- d3443b929babd2daf7d6ae90395d546356fda173
- Cited by
- 628
- References
- 22
- Citations by year
- 2026: 13 · 2025: 31 · 2024: 28 · 2023: 28 · 2022: 33 · 2021: 35 · 2020: 32 · 2019: 41 · 2018: 46 · 2017: 46 · 2016: 52 · 2015: 66 · 2014: 68 · 2013: 77 · 2012: 29
- FWCI
- 61.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- pasireotide, Cushing's disease, somatostatin receptor type 5, somatostatin analogues, urinary free cortisol, hypercortisolism, hyperglycemia, HbA1c, dose escalation
- MeSH terms
- Adolescent, Adrenocorticotropic Hormone, Adult, Aged, Child, Double-Blind Method, Female, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Saliva, Somatostatin, Pituitary ACTH Hypersecretion, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
